Sana Biotechnology Inc vs Clear Secure Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $947.48M), while Clear Secure Inc trades at $43.42 (market cap $4.45B). The key difference: Clear Secure Inc is far larger — about 4.7× Sana Biotechnology Inc's market cap, and Clear Secure Inc pays a 1.33% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | YOU | |
|---|---|---|
Market Cap | $947.48M | $4.45B |
Sector | Health | Technology |
52-Week High | $5.92 | $62.36 |
52-Week Low | $2.68 | $29.61 |
Enterprise Value | $860.73M | $3.60B |
Dividend Yield | — | 1.33% |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Clear Secure (YOU) trades at $43.6, down 1.65% in the last session, with a bearish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with $0.49 EPS and 27% revenue growth, while expanding its identity platform through partnerships like CrowdStrike. Profitability metrics show robust gross margins of 66.66% and high ROE of 90.29%, though valuation ratios like P/E of 29.17 suggest premium pricing.
Outlook remains mixed: growth catalysts include membership expansion and enterprise deals, but risks involve insider selling and competitive pressures. Analysts are divided with a 44% buy rating, highlighting potential upside if execution continues, though technical weakness near support at $42 warrants caution for near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →